This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
n24http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n17http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/bindingdb/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/kegg-compound/
n5http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01246/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01246
rdf:type
n3:Drug
n3:description
A phenothiazine derivative that is used as an antipruritic. [PubChem]
n3:group
approved
n3:indication
Used to prevent and relieve allergic conditions which cause pruritus (itching) and urticaria (some allergic skin reactions).
owl:sameAs
n12:DB01246 n17:DB01246
dcterms:title
Alimemazine
adms:identifier
n5:5574 n7:46508449 n8:C07172 n9:DB01246 n10:50062261 n13:5373 n19:PA164744009
n3:mechanismOfAction
Trimeprazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
n3:packager
n16:271B5E7A-363D-11E5-9242-09173F13E4C5
n3:synonym
Trimeprazine Repeltin Alimemazine Methylpromazine
n3:toxicity
Symptoms of overdose clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.
n20:hasAHFSCode
n21:04-04-12
n3:mixture
n15:271B5E78-363D-11E5-9242-09173F13E4C5 n15:271B5E79-363D-11E5-9242-09173F13E4C5
n3:salt
n23:hasConcept
n24:M0021986
n3:IUPAC-Name
n6:271B5E81-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5E87-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5E86-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5E83-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5E84-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5E85-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5E7F-363D-11E5-9242-09173F13E4C5 n6:271B5E96-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5E99-363D-11E5-9242-09173F13E4C5 n6:271B5E80-363D-11E5-9242-09173F13E4C5 n6:271B5E7D-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5E7E-363D-11E5-9242-09173F13E4C5
n3:pKa
n6:271B5E9A-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n22:R06AD01
n3:H-Bond-Acceptor-Count
n6:271B5E8D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5E8E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5E88-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5E89-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5E8B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5E8A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5E8C-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed in the digestive tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
84-96-8
n3:category
n3:containedIn
n18:271B5E7B-363D-11E5-9242-09173F13E4C5 n18:271B5E7C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5E92-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n6:271B5E98-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5E94-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5E95-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5E97-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5E91-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5E90-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5E93-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5E82-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5E8F-363D-11E5-9242-09173F13E4C5